心肌灌注显像剂~(99m)Tc-Tetrofosmin临床应用的研究

目的：通过与冠状动脉造影比较,评价９９ｍＴｃ－ Ｔｅｔｒｏｆｏｓｍｉｎ心肌灌注显像在冠心病诊断中的价值。方法：对 ２４例受检者（ＣＨＤ１４例,非 ＣＨＤ１０例）进行静息和运动负荷状态下的９９ｍＴｃ－ Ｔｅｔｒｏｆｏｓｍｉｎ心肌 ＳＰＥＣＴ显像,同期也行冠状动脉造影。结果：以冠状动脉造影为金标准,９９ｍＴｃ－Ｔｅｔｒｏｆｏｓｍｉｎ心肌 ＳＰＥＣＴ显像诊断冠心病的灵敏度、特异性和准确率分别为９２．３％,６０％和７８．３％。结论：９９ｍＴｃ－Ｔｅｔｒｏｆｏｓｍｉｎ心肌灌注显像在冠心病诊断中具有较高的临床价值。     

99Tcm-HL91乏氧显像在恶性肿瘤治疗后随访中的应用

Objective 99Tcm-4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime (HL91) is a new hypoxia imaging agent that demonstrates increased uptake and retention in tumor hypoxic tissues in vivo. The objective of this study was to evaluate the clinical value of 99Tcm-HL91 hypoxia imaging in post-therapeutic patients with cancers. Methods Thirty-seven patients with primary cancers at head and neck and upper aerodigestive region who were suspected to have residual, recurrent, or metastatic disease at either clinical follow-up or by regular CT follow-up, were included. All underwent 99Tcm-HL91 imaging. The radioactivity ratios of tumor to normal tissues (T/NT) were calculated using the region of interest (ROI) technique. A t-test was used for data analysis. The " gold standard" of diagnostic accuracy was based on histopathology or clinical follow-up. Results were compared between 99Tcm-HL91 and CT. Results Of the 37 patients, 11 had either residual or recurrent lesions and 7 had distant disease. (1) A significantly higher 99Tcm-HL91 uptake were noted in residual or recurrent lesions than benign lesions (1.58 ± 0. 16 vs 1.18 ±0.14, t =4. 87, P <0.001). (2) The sensitivity, specificity, and accuracy for residual or recur-rent lesions were 72. 73% (8/11), 63.64% (7/11), 4/4; 89.47% (17/19), 84. 21% (16/19), 94. 12% (16/17), and 83.33% (25/30), 76.67% (23/30), 95.24% (20/21) in 99Tcm-HL91, CT, and combined 99Tcm-HL91 and CT, respectively. (3) For distant sites detection (n = 7), CT detected all but 99Tcm-HL91 missed three. Conclusions A combination of 99Tcm-HL91 and CT in detection either residu-al, recurrent, or metastatic disease would have the highest benefit in patients with cancers at head and neck and upper aerodigestive region.     

血清肿瘤标志物预测乳腺癌骨转移的价值

目的探讨血清肿瘤标志物预测乳腺癌骨转移的临床价值。方法应用化学发光免疫检测技术检测174例乳腺癌患者血清CA153、CA125、CEA、FER等四种肿瘤标志物,同时应用SPECT对所有患者行全身骨扫描检查,以明确有无骨转移。结果174例患者中55例临床诊断为乳腺癌骨转移。CA153、CA125、CEA、FER对诊断骨转移的阳性预测价值分别为68.0%(34/50),70.0%(14/20),88.9%(8/9),53.8%(14/26),阴性预测价值分别为86.2%(106/123),89.0%(130/146),73.2%(115/157),75.9%(85/112)。一种以上标志物同时阳性或阴性者,其阳性或阴性预测价值增加。结论CA153、CA125、CEA、FER具有预测乳腺癌骨转移的临床价值,联合检测CA153、CA125、CEA、FER能提高其预测乳腺癌骨转移的准确性。     

99Tcm-HL91乏氧显像在恶性肿瘤治疗后随访中的应用

Objective 99Tcm-4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime (HL91) is a new hypoxia imaging agent that demonstrates increased uptake and retention in tumor hypoxic tissues in vivo. The objective of this study was to evaluate the clinical value of 99Tcm-HL91 hypoxia imaging in post-therapeutic patients with cancers. Methods Thirty-seven patients with primary cancers at head and neck and upper aerodigestive region who were suspected to have residual, recurrent, or metastatic disease at either clinical follow-up or by regular CT follow-up, were included. All underwent 99Tcm-HL91 imaging. The radioactivity ratios of tumor to normal tissues (T/NT) were calculated using the region of interest (ROI) technique. A t-test was used for data analysis. The " gold standard" of diagnostic accuracy was based on histopathology or clinical follow-up. Results were compared between 99Tcm-HL91 and CT. Results Of the 37 patients, 11 had either residual or recurrent lesions and 7 had distant disease. (1) A significantly higher 99Tcm-HL91 uptake were noted in residual or recurrent lesions than benign lesions (1.58 ± 0. 16 vs 1.18 ±0.14, t =4. 87, P <0.001). (2) The sensitivity, specificity, and accuracy for residual or recur-rent lesions were 72. 73% (8/11), 63.64% (7/11), 4/4; 89.47% (17/19), 84. 21% (16/19), 94. 12% (16/17), and 83.33% (25/30), 76.67% (23/30), 95.24% (20/21) in 99Tcm-HL91, CT, and combined 99Tcm-HL91 and CT, respectively. (3) For distant sites detection (n = 7), CT detected all but 99Tcm-HL91 missed three. Conclusions A combination of 99Tcm-HL91 and CT in detection either residu-al, recurrent, or metastatic disease would have the highest benefit in patients with cancers at head and neck and upper aerodigestive region.     

32磷敷贴治疗增生性瘢痕和瘢痕疙瘩疗效观察

３２磷敷贴治疗增生性瘢痕和瘢痕疙瘩疗效观察苏新辉盛荣宗林月华俞浩毛利娜俞丹男５１例，女７２例，年龄６个月～６６岁，病程３个月～１８年，其中增生性瘢痕２６例，瘢痕疙瘩９７例。治疗方法按常规方法制备３２磷敷贴器。每次辐射剂量６～８Ｇｙ／ｃｍ２，日１次，５...     

核素-蓝染法探测乳腺癌前哨淋巴结的临床价值(附27例分析)

目的评价~(99)Tc~m-硫胶体和美蓝联合应用探测乳腺癌前哨淋巴结(SLN)的临床价值。方法27例早期乳腺癌患者,年龄(29～64)岁,采用99Tcm-硫胶体和美蓝联合探测SLN,以腋窝淋巴结(ALN)病理检查结果作为评价标准。结果27例患者SLN的检出率92.6%,探测的准确性96.0%,灵敏度90.0%,假阴性率10.0%,阴性预测值93.8%。结论乳腺癌SLN探测可预测ALN的转移状况,为外科医生确定手术方式提供重要信息。     

^99Tc^m-HL91乏氧显像在恶性肿瘤治疗后随访中的应用

目的评价^99Tc^m-4,9-二氮-3,3,10,10-四甲基十二烷-2,11-二酮肟（HL91）乏氧显像在恶性肿瘤治疗后随访中的价值。方法37例胸部和头颈部恶性肿瘤患者在治疗结束后3—12个月的临床随访中,CT检查怀疑肿瘤残余、复发或转移,再行^99Tc^m-HL91乏氧显像。目测定性分析,判定乏氧显像阳性病例,再用感兴趣区（ROI）技术对阳性病例进行半定量分析,计算肿瘤部位（T）与对侧相应部位或头皮（NT）的放射性比值（T／NT）,并采用成组设计两样本均数t检验进行比较。以鼻咽内镜检查、病理活组织检查结果和12个月的临床随访资料作为判断肿瘤残余、复发或转移的依据,计算^99Tc^m-HL91显像和cT的诊断效能。结果37例患者中,无肿瘤局部残余或复发病灶者19例,存在肿瘤局部残余或复发病灶者11例,有远处转移病灶者7例。（1）无肿瘤局部残余或复发组与肿瘤局部残余或复发组的T／NT比值分别为1．18±0．14和1．58±0．16,两者差异有统计学意义（t=4．87,P〈0．001）。（2）^99Tc^m-HL91显像监测肿瘤局部残余或复发的灵敏度72．73％（8／11）,特异性89．47％（17／19）,准确性83．33％（25／30）;CT监测肿瘤局部残余或复发的灵敏度63．64％（7／11）,特异性84．21％（16／19）,准确性76．67％（23／30）。^99Tc^m-HL91显像与CT结果一致的有21例患者,^99Tc^m-HL91显像与CT联合监测此21例肿瘤残余或复发的灵敏度4／4,特异性94．12％（16／17）,准确性95．24％（20／21）。（3）7例转移患者,^99Tc^m-HL91显像阳性4例,CT均阳性。结论^99Tc^m-HL91乏氧显像对恶性肿瘤治疗后局部残余、复发或转移灶的鉴别有一定价值,与CT联合可有效提高对恶性肿瘤治疗后局部残余、复发或转移灶的早期诊断效能。     

99mTc-MIBI显像定位诊断甲状旁腺功能亢进的临床价值

目的：评价＾９９ｍＴｃ－ＭＩＢＩ显像在定位诊断早状旁腺功能亢进中的价值。材料和方法：３０例临床诊断或高度怀疑甲旁亢患者于颈部及上胸部行＾９９ｍＴｃ－ＭＩＢＩ显像,采用双时相法（１５ｍｉｎ即刻相及１２０ｍｉｎ延迟相）并加做＾９９ｍＴｃ－ＭＩＢＩ全身显像,同期做Ｂ超（３０例）和ＣＴ检查（１０例）。结果：与手术病理结果对照,＾９９ｍＴｃ－ＭＩＢＩ显像、Ｂ超和ＣＴ诊断准确性分别为８３．３％、６３．３％和７０％,对于正常位置、异位、术后复发,＾９９ｍＴｃ－ＭＩＢＩ显像阳性检出率均较Ｂ超、ＣＴ高。结论：＾９９ｍＴｃ－ＭＩＢＩ显像在定位诊断甲状旁腺功能亢进疾患具有较高临床价值,万其对异位和术后复发及确定有无三发性甲旁亢的敏感性优于Ｂ超、ＣＴ,可作为甲状旁腺功能亢进症术前定位诊断的主要手段。     

99Tcm-HL91乏氧显像在恶性肿瘤治疗后随访中的应用

Objective 99Tcm-4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime (HL91) is a new hypoxia imaging agent that demonstrates increased uptake and retention in tumor hypoxic tissues in vivo. The objective of this study was to evaluate the clinical value of 99Tcm-HL91 hypoxia imaging in post-therapeutic patients with cancers. Methods Thirty-seven patients with primary cancers at head and neck and upper aerodigestive region who were suspected to have residual, recurrent, or metastatic disease at either clinical follow-up or by regular CT follow-up, were included. All underwent 99Tcm-HL91 imaging. The radioactivity ratios of tumor to normal tissues (T/NT) were calculated using the region of interest (ROI) technique. A t-test was used for data analysis. The " gold standard" of diagnostic accuracy was based on histopathology or clinical follow-up. Results were compared between 99Tcm-HL91 and CT. Results Of the 37 patients, 11 had either residual or recurrent lesions and 7 had distant disease. (1) A significantly higher 99Tcm-HL91 uptake were noted in residual or recurrent lesions than benign lesions (1.58 ± 0. 16 vs 1.18 ±0.14, t =4. 87, P <0.001). (2) The sensitivity, specificity, and accuracy for residual or recur-rent lesions were 72. 73% (8/11), 63.64% (7/11), 4/4; 89.47% (17/19), 84. 21% (16/19), 94. 12% (16/17), and 83.33% (25/30), 76.67% (23/30), 95.24% (20/21) in 99Tcm-HL91, CT, and combined 99Tcm-HL91 and CT, respectively. (3) For distant sites detection (n = 7), CT detected all but 99Tcm-HL91 missed three. Conclusions A combination of 99Tcm-HL91 and CT in detection either residu-al, recurrent, or metastatic disease would have the highest benefit in patients with cancers at head and neck and upper aerodigestive region.     

PYGO2基因RNA干扰真核表达载体的构建

目的构建PYGO2基因RNA干扰（RNAi）的真核细胞表达载体。方法以PYGO2为靶基因,以pSUPER．puro质粒为载体,设计构建重组体,根据基因库（GenBank）提供的PYGO2基因核苷酸序列,在http：／／www．ambion．com网站上使用siRNA Target Finder软件进行目的基因的siRNA序列对应DNA的设计与筛选,选择设计两条带发夹结构的核苷酸序列,克隆到空载体pSUPER．puro中,转化DH5α菌株,提取质粒,进行限制性内切酶酶切鉴定和测序分析,将重组的pSUPER．puro-PYGO2质粒转染胶质瘤C6细胞48h,检测其对该细胞PYGO2蛋白的影响。结果经酶切鉴定筛选出的重组体测序结果与目的序列完全一致,重组载体显著降低胶质瘤细胞PYGO2的蛋白表达,重组载体构建成功。结论利用RNAi技术可成功构建抑制PYGO2表达的siRNA真核表达载体。